MyChoice, a Canadian insurtech improving submission quality and underwriting confidence in the broker and carrier channels, announced that the company has joined the Guidewire Insurtech Vanguards ...
Myriad Genetics, Inc. MYGN recently submitted a supplementary premarket approval (sPMA) application to the FDA for its myChoice CDx test. This will enable the identification of women suffering from ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...
The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the FDA ...
Myriad Genetics, Inc. MYGN recently announced the receipt of additional reimbursement in Japan for its myChoice Diagnostic System. Notably, the test aids in identifying patients with advanced ovarian ...
SALT LAKE CITY, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that the U.S. Food and Drug Administration ...
WEST DES MOINES, Iowa, Sept. 23, 2020 /PRNewswire/ -- A series of special reports released this month by Businessolver®, a leader in SaaS-based benefits technology and services, expose how COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results